Langen K J, Roosen N, Herzog H, Kuwert T, Kiwit J C, Bock W J, Feinendegen L E
Institute of Medicine, Nuclear Research Center Jülich, FRG.
Nucl Med Commun. 1989 May;10(5):325-34. doi: 10.1097/00006231-198905000-00003.
The cerebral uptake of 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HMPAO) as measured with the use of single photon emission computed tomography (SPECT) was studied in 66 patients with various types of brain tumours and quantified by tumour-to-cerebellum ratios. The uptake of 99Tcm-HMPAO by gliomas and meningiomas showed wide ranges of values. There were no significant differences among primary malignant gliomas (0.75 +/- 0.27, n = 25), recurrent malignant gliomas (0.81 +/- 0.25, n = 14) and benign gliomas (0.77 +/- 0.21, n = 9). Compared to gliomas, meningiomas exhibited a significantly higher 99Tcm-HMPAO uptake (1.14 +/- 0.31, n = 13, p less than 0.001) while the remaining four patients with tumours of various histopathology showed a low 99Tcm-HMPAO uptake. Three of the 66 patients were scanned immediately and again 2 h after injection and they revealed a decrease in tumour activity. No changes in the pattern of uptake were observed in two patients with gliomas which were studied before and after intra-arterial chemotherapy, but a decrease in tumour uptake was found in the glioma patient who was studied before and after radiotherapy. The results obtained with 99Tcm-HMPAO SPECT are in agreement with those on regional cerebral blood flow (rCBF) in brain tumours reported in the literature.
利用单光子发射计算机断层扫描（SPECT）测量了66例不同类型脑肿瘤患者大脑对99锝-六甲基丙烯胺肟（99Tcm-HMPAO）的摄取情况，并通过肿瘤与小脑摄取比值进行量化。胶质瘤和脑膜瘤对99Tcm-HMPAO的摄取显示出广泛的数值范围。原发性恶性胶质瘤（0.75±0.27，n = 25）、复发性恶性胶质瘤（0.81±0.25，n = 14）和良性胶质瘤（0.77±0.21，n = 9）之间无显著差异。与胶质瘤相比，脑膜瘤对99Tcm-HMPAO的摄取显著更高（1.14±0.31，n = 13，p＜0.001），而其余4例不同组织病理学类型肿瘤的患者对99Tcm-HMPAO的摄取较低。66例患者中有3例在注射后立即及2小时后再次进行扫描，结果显示肿瘤活性降低。2例接受动脉内化疗前后进行研究的胶质瘤患者，其摄取模式未观察到变化，但1例接受放疗前后进行研究的胶质瘤患者发现肿瘤摄取降低。99Tcm-HMPAO SPECT获得的结果与文献中报道的脑肿瘤区域脑血流量（rCBF）的结果一致。
